Revisiting the design of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria

PLoS Medicine

Volumn 5, Issue 11, 2008, Pages 1546-1552

  Borrmann, Steffen ^a,b   Peto, Tim ^c   Snow, Robert W ^a,d   Gutteridge, Win ^e   White, Nicholas J ^d,f  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e Medicines for Malaria Venture   (Switzerland)

^f MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT;

CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; FOLLOW UP; HUMAN; IMMUNITY; MALARIA FALCIPARUM; MINIMUM INHIBITORY CONCENTRATION; PHARMACOGENETICS; PLASMODIUM FALCIPARUM; PROPHYLAXIS; REVIEW; TREATMENT FAILURE; ANIMAL; ARTICLE; DRUG COMBINATION; DRUG EFFECT; MORTALITY; PARASITOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); RECURRENT DISEASE; SURVIVAL; TREATMENT OUTCOME;

ANIMALS; ANTIMALARIALS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 56749176780     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0050227     Document Type: Review

References (53)

1. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI (2005) The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434: 214-217.
2. Marsh K, Forster D, Waruiru C, Mwangi I, Winstanley M, et al. (1995) Indicators of life-threatening malaria in African children. N Engl J Med 332: 1399-1404.
3. Snow RW, Marsh K (2002) The consequences of reducing transmission of Plasmodium falciparum in Africa. Adv Parasitol 52: 235-264.
4. Snow RW, Trape JF, Marsh K (2001) The past, present and future of childhood malaria mortality in Africa. Trends Parasitol 17: 593-597.
5. Snow RW, Eckert E, Teklehaimanot A (2003) Estimating the needs for artesunate-based combination therapy for malaria case-management in Africa. Trends Parasitol 19: 363-369.
6. Mutabingwa TK (2005) Artemisinin-based combination therapies (ACTs): Best hope for malaria treatment but inaccessible to the needy! Acta Trop 95: 305-315.
7. Bathurst I, Hentschel C (2006) Medicines for Malaria Venture: Sustaining antimalarial drug development. Trends Parasitol 22: 301-307.
8. Amin AA, Zurovac D, Kangwana BB, Greenfield J, Otieno DN, et al. (2007) The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. Malar J 6: 72.
9. Stepniewska K, White NJ (2006) Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Malar J 5: 127.
10. Kamya MR, Yeka A, Bukirwa H, Lugemwa M, Rwakimari JB, et al. (2007) Artemetherlumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: A randomized trial. PLoS Clin Trials 2: e20. doi:10.1371/journal.pctr. 0020020
11. Staedke SG, Mpimbaza A, Kamya MR, Nzarubara BK, Dorsey G, et al. (2004) Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: Randomised clinical trial. Lancet 364: 1950-1957.
12. Uhlemann AC, McGready R, Ashley EA, Brockman A, Singhasivanon P, et al. (2007) Intrahost selection of Plasmodium falciparum pfmdr1 alleles after antimalarial treatment on the northwestern border of Thailand. J Infect Dis 195: 134-141.
13. Bhattarai A, Ali AS, Kachur SP, Martensson A, Abbas AK, et al. (2007) Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med 4: e309. doi:10.1371/journal.pmed.0040309
14. World Health Organization (2008) Methods and techniques for clinical trials on antimalarial drug efficacy. Available: http://www.who.int/malaria/ docs/drugresistance/MalariaGenotyping.pdf. Accessed 10 October 2008.
15. Laufer MK, Djimde AA, Plowe CV (2007) Monitoring and deterring drug-resistant malaria in the era of combination therapy. Am J Trop Med Hyg 77: 160-169.
16. Borrmann S, Matsiegui PB, Missinou MA, Kremsner PG (2008) Effects of Plasmodium falciparum parasite population size and patient age on early and late parasitological outcomes of antimalarial treatment in children. Antimicrob Agents Chemother 52: 1799-1805.
17. Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, et al. (2005) Supervised versus unsupervised intake of six-dose artemetherlumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: A randomised trial. Lancet 365: 1467-1473.
18. Price RN, Dorsey G, Ashley EA, Barnes KI, Baird JK, et al. (2007) World Antimalarial Resistance Network I: Clinical efficacy of antimalarial drugs. Malar J 6: 119.
19. Barnes KI, Watkins WM, White NJ (2008) Antimalarial dosing regimens and drug resistance. Trends Parasitol 24: 127-134.
20. White NJ (1997) Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 41: 1413-1422.
21. Djimde AA, Doumbo OK, Traore O, Guindo AB, Kayentao K, et al. (2003) Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg 69: 558-563.
22. Stepniewska K, Taylor WR, Mayxay M, Price R, Smithuis F, et al. (2004) In vivo assessment of drug efficacy against Plasmodium falciparum malaria: Duration of follow-up. Antimicrob Agents Chemother 48: 4271-4280.
23. Price RN, Uhlemann AC, van Vugt M, Brockman A, Hutagalung R, et al. (2006) Molecular and pharmacological determinants of the therapeutic response to artemetherlumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis 42: 1570-1577.
24. Epstein JE, Rao S, Williams F, Freilich D, Luke T, et al. (2007) Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: An update. J Infect Dis 196: 145-154.
25. Guthmann JP, Pinoges L, Checchi F, Cousens S, Balkan S, et al. (2006) Methodological issues in the assessment of antimalarial drug treatment: Analysis of 13 studies in eight African countries from 2001 to 2004. Antimicrob Agents Chemother 50: 3734-3739.
26. Lee SA, Yeka A, Nsobya SL, Dokomajilar C, Rosenthal PJ, et al. (2006) Complexity of Plasmodium falciparum infections and antimalarial drug efficacy at 7 sites in Uganda. J Infect Dis 193: 1160-1163.
27. Slater M, Kiggundu M, Dokomajilar C, Kamya MR, Bakyaita N, et al. (2005) Distinguishing recrudescences from new infections in antimalarial clinical trials: Major impact of interpretation of genotyping results on estimates of drug efficacy. Am J Trop Med Hyg 73: 256-262.
28. Gatton ML, Cheng Q (2008) Can estimates of antimalarial efficacy from field studies be improved? Trends Parasitol 24: 68-73.
29. Collins WJ, Greenhouse B, Rosenthal PJ, Dorsey G (2006) The use of genotyping in antimalarial clinical trials: A systematic review of published studies from 1995-2005. Malar J 5: 122.
30. Farnert A, Arez AP, Babiker HA, Beck HP, Benito A, et al. (2001) Genotyping of Plasmodium falciparum infections by PCR: A comparative multicentre study. Trans R Soc Trop Med Hyg 95: 225-232.
31. Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim JR, et al. (2007) Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis 195: 927-933.
32. World Health Organization (2003) Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Available: http://www.who.int/malaria/docs/ProtocolWHO.pdf. Accessed 10 October 2008.
33. White NJ (2008) How antimalarial drug resistance affects post-treatment prophylaxis. Malar J 7: 9.
34. Olliaro P, Pinoges L, Checchi F, Vaillant M, Guthmann JP (2008) Risk associated with asymptomatic parasitaemia occurring post-antimalarial treatment. Trop Med Int Health 13: 83-90.
35. Smith T, Schellenberg JA, Hayes R (1994) Attributable fraction estimates and case definitions for malaria in endemic areas. Stat Med 13: 2345-2358.
36. Staedke SG, Kamya MR, Dorsey G, Gasasira A, Ndeezi G, et al. (2001) Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: A randomised trial. Lancet 358: 368-374.
37. Zongo I, Dorsey G, Rouamba N, Tinto H, Dokomajilar C, et al. (2007) Artemetherlumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: A randomised non-inferiority trial. Lancet 369: 491-498.
38. Greenhouse B, Dokomajilar C, Hubbard A, Rosenthal PJ, Dorsey G (2007) Impact of transmission intensity on the accuracy of genotyping to distinguish recrudescence from new infection in antimalarial clinical trials. Antimicrob Agents Chemother 51: 3096-3103.
39. Nwaka S, Hudson A (2006) Innovative lead discovery strategies for tropical diseases. Nat Rev Drug Discov 5: 941-955.
40. Medicines for Malaria Venture (2008) Target product profile. Available: http://www.mmv.org/IMG/pdf/PRODUCT_PROFILE_with_logo.pdf. Accessed 10 October 2008.
41. World Health Organization (2006) Guidelines for the treatment of malaria. Available: http://www.who.int/malaria/docs/TreatmentGuidelines2006.pdf. Accessed 10 October 2008.
42. Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, et al. (2007) Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: An open-label randomised comparison. Lancet 369: 757-765.
43. Tarning J, Lindegardh N, Annerberg A, Singtoroj T, Day NP, et al. (2005) Pitfalls in estimating piperaquine elimination. Antimicrob Agents Chemother 49: 5127-5128.
44. Schulz KF, Grimes DA (2002) Generation of allocation sequences in randomised trials: Chance, not choice. Lancet 359: 515-519.
45. Myint HY, Tipmanee P, Nosten F, Day NP, Pukrittayakamee S, et al. (2004) A systematic overview of published antimalarial drug trials. Trans R Soc Trop Med Hyg 98: 73-81.
46. Jones B, Jarvis P, Lewis JA, Ebbutt AF (1996) Trials to assess equivalence: The importance of rigorous methods. BMJ 313: 36-39.
47. European Medicines Agency (2005) Guideline on the choice of the non-inferiority margin. Available: http://www.sctweb.org/presentations/2008/ GuidelineontheChoiceoftheNoninferiorityMargin.pdf. Accessed 10 October 2008.
48. European Medicines Agency (2000) Points to consider on switching between superiority and non-inferiority. Available: http://www.emea.europa.eu/pdfs/ human/ewp/048299en.pdf. Accessed 10 October 2008.
49. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ (2006) Reporting of noninferiority and equivalence randomized trials: An extension of the CONSORT statement. JAMA 295: 1152-1160.
50. Machekano R, Dorsey G, Hubbard A (2008) Efficacy studies of malaria treatments in Africa: Efficient estimation with missing indicators of failure. Stat Methods Med Res 17: 191-206.
51. Rothmann M, Li N, Chen G, Chi GY, Temple R, et al. (2003) Design and analysis of non-inferiority mortality trials in oncology. Stat Med 22: 239-264.
52. US Food and Drug Administartion (2007) Guidance for industry. Antibacterial drug products: Use of noninferiority studies to support approval. Available: http://www.fda.gov/Cder/guidance/7884dft.htm. Accessed 10 October 2008.
53. Price RN, Hasugian AR, Ratcliff A, Siswantoro H, Purba HL, et al. (2007) Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrob Agents Chemother 51: 4090-4097.